This month, Lockheed Martin formally announced its acquisition of the government business unit of Nantero, Inc., a privately-held, Massachusetts-based company that develops methods and processes for incorporating carbon nanotubes for electronic devices. It is expected that about 30 Nantero employees will join Lockheed Martin as part of the agreement, including Dr. Brent Segal, Nantero

The FDA Nanotechnology Public Meeting will take place September 8, 2008. Agenda items include an overview of the FDA Nanotechnology Task Force Findings, and breakout sessions that will include discussions about nanotechnology for medical devices, prescription drugs, food, and cosmetics. For more information about the meeting, please visit:

We established that melanin-based nanoshells can be used in the protection of human beings and machinery from electromagnetic radiation, in particular, from ionizing radiation, and in energy conversion such as minimizing the losses during energy transfer.

Cambridge Biomagnetics (CBM) aims to provide a range of solutions to enable next generation biochemical assays with high speed and reliability in a true multiplexed manner. CBM is utilising its platform technology for magnetically tagging vast numbers of chemical and biological compounds for a plethora of applications covering the life sciences and diagnostic industries.

An optically addressed drug delivery system with multicompartment lipid vesicles, called vesosomes, that also encapsulate gold nanoshells. The vesosome provide a biocompatible environment that sequesters a wide variety of drugs much more efficiently than conventional liposomes, while still having extended circulation in the body.

Portable electronic devices continuously need more power. The miniaturized Solid Oxide Fuel Cell (micro SOFC) is a hybrid power source, directly fueled by butane, with an increased energy capacity and density compared to current Li-ion batteries.

The capability of design and fabrication of nanometer-sized functional materials are highly desired in nanotechnology due to their potential use as building blocks in nanodevices.

In a study with breast cancer in mice, a nanotech cancer therapy suppresses tumor growth with minimal side effects. Taking advantage of the fact that the blood vessels in tumor tissue are leakier than in normal tissue, carbon nanotubes of the right size and with the proper chemical coating deliver more tumor-killing drug to tumors, while sparing normal tissue. In future experiments, the researchers may add molecules that specifically target tumor cells to achieve even greater specificity. ScienceDaily features a story from Stanford University News, written by Louis Bergeron “Nanotubes deliver high-potency punch to cancer tumors in mice“:

The problem with using a shotgun to kill a housefly is that even if you get the pest, you’ll likely do a lot of damage to your home in the process. Hence the value of the more surgical flyswatter.

Cancer researchers have long faced a similar situation in chemotherapy: how to get the most medication into the cells of a tumor without “spillover” of the medication adversely affecting the healthy cells in a patient’s body.

Now researchers at Stanford University have addressed that problem using single-walled carbon nanotubes as delivery vehicles. The new method has enabled the researchers to get a higher proportion of a given dose of medication into the tumor cells than is possible with the “free” drug—that is, the one not bound to nanotubes—thus reducing the amount of medication that they need to inject into a subject to achieve the desired therapeutic effect.

“That means you will also have less drug reaching the normal tissue,” said Hongjie Dai, professor of chemistry and senior author of a paper, which will be published in the Aug. 15 issue of Cancer Research [abstract]. So not only is the medication more effective against the tumor, ounce for ounce, but it greatly reduces the side effects of the medication.

Graduate student Zhuang Liu is first author of the paper.

Dai and his colleagues worked with paclitaxel, a widely used cancer chemotherapy drug, which they employed against tumors cells of a type of breast cancer that were implanted under the skin of mice. They found that they were able to get up to 10 times as much medication into the tumor cells via the nanotubes as when the standard formulation of the drug, called Taxol®, was injected into the mice.

The tumor cells were allowed to proliferate for about two weeks prior to being treated. After 22 days of treatment, tumors in the mice treated with the paclitaxel-bearing nanotubes were on average less than half the size of those in mice treated with Taxol.

Critical to achieving those results were the size and surface structure of the nanotubes, which governed how they interacted with the walls of the blood vessels through which they circulated after being injected. Though a leaky vessel—nautical or anatomical—is rarely a good thing, in this instance the relatively leaky walls of blood vessels in the tumor tissue provided the opening that the nanotubes needed to slip into the tumor cells.

“The results are actually highly dependent on the surface chemistry,” Dai said. “In other words, you don’t get this result just by attaching drugs to any nanotubes.”

The researchers used nanotubes that they had coated with polyethylene glycol (PEG), a common ingredient in cosmetics. The PEG they used was a form that has three little branches sprouting from a central trunk. Stuffing the trunks into the linked hexagonal rings that make up the nanotubes created a visual effect that Dai described as looking like rolled-up chicken wire with feathers sticking out all over. The homespun sounding appearance notwithstanding, the nanotubes proved to be highly effective delivery vehicles when the researchers attached the paclitaxel to the tips of the branches.

…Dai said that the technique holds potential for delivering a range of medications and that it may also be possible to develop ways to channel the nanotubes to their target even more precisely.

“Right now what we are doing is so-called ‘passive targeting,’ which is using the leaky vasculature of the tumor,” he said. “But a more active targeting would be attaching a peptide or antibody to the nanotube drug, one that will bind more specifically to the tumor, which should further enhance the treatment efficacy.”

Dai’s team is already at work developing more targeted approaches, and he is optimistic about the potential applications of nanotubes.

“We are definitely hoping to be able to push this to practical applications into the clinic. This is one step forward,” he said. “But it will still take time to truly prove the efficacy and the safety.”

—Jim